Evidence map›Paper›PMID 40595054›Full record

ArticleScientific reports2025

Computational investigation of Belzutifan drug delivery mechanisms using SiC nanocrystals via combined DFT and molecular dynamics approaches.

Wael A Mahdi, Adel Alhowyan, Ahmad J Obaidullah

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wael A MahdiDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia. wmahdi@ksu.edu.sa.
Adel AlhowyanDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia. Adel-ali@ksu.edu.sa.
Ahmad J ObaidullahDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia.

Funding

King Saud University ORF-2025-516
6 · The paper itself

Abstract

This study employs density functional theory (DFT) and molecular dynamics (MD) simulations to investigate silicon carbide (SiC) nanocrystals as carriers for the anticancer drug Belzutifan. Among tested functional groups (-H, -OH, -NH₂, -COOH), carboxyl-functionalized SiC (SiC-COOH) exhibits superior drug loading capacity with an adsorption energy of -1.03 eV, representing a 25% improvement over conventional carbon-based carriers. The SiC-COOH system demonstrates exceptional stability with a formation energy of -5.42 eV/atom and a remarkably high dipole moment of 142.1 D, facilitating enhanced solubility. Electronic structure analysis reveals significant charge transfers (-0.25e) from Belzutifan to the nanocrystal, accompanied by a substantial reduction in the HOMO-LUMO gap from 5.427 eV (pristine SiC) to 3.41 eV (Belzutifan@SiC-COOH complex), indicating improved electronic coupling. MD simulations confirm the complex's stability under physiological conditions, maintaining structural integrity with root-mean-square deviation (RMSD) values below 2.5 Å throughout the 5 ps simulation. Characteristic shifts in optical spectra (200-600 nm range) and IR vibrational modes (15-40 cm⁻¹) provide clear spectroscopic signatures of successful drug adsorption. The combination of strong binding (-1.03 eV adsorption energy), maintained biocompatibility, and tunable electronic properties positions functionalized SiC nanocrystals as a promising platform for targeted Belzutifan delivery, with potential applications in photo-triggered release systems.

Indexed as

Carbon Compounds, InorganicDrug Delivery SystemsMolecular Dynamics SimulationNanoparticlesSilicon CompoundsAntineoplastic AgentsDensity Functional TheoryDrug CarriersIndenesAntineoplastic AgentsbelzutifanCarbon Compounds, InorganicDrug CarriersIndenessilicon carbideSilicon CompoundsBelzutifanDFTDrug deliveryMDSiC nanocrystals

Identifiers

PMID40595054
PMCPMC12216662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.